The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
about
Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugsCarbocations in the synthesis of prostaglandins by the cyclooxygenase of PGH synthase? A radical departure!Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosaAntiplatelet therapy for carotid artery stentingContribution of blood platelets to vascular pathology in Alzheimer's diseaseOxicams, a class of nonsteroidal anti-inflammatory drugs and beyondMutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthasesStructure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1Comparison of Cyclooxygenase-1 Crystal Structures: Cross-Talk between Monomers Comprising Cyclooxygenase-1 Homodimers,The structure of NS-398 bound to cyclooxygenase-2Oxicams Bind in a Novel Mode to the Cyclooxygenase Active Site via a Two-water-mediated H-bonding NetworkAspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 angstroms resolutionThe cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confoundingResistance to antiplatelet drugs: current status and future researchEffects of enteric-coated, low-dose aspirin on parameters of platelet functionRole of Tyr348 in Tyr385 radical dynamics and cyclooxygenase inhibitor interactions in prostaglandin H synthase-2Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsPlatelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patientsRecent FDA warning of the concomitant use of aspirin and ibuprofen and the effects on platelet aggregationInsight into steroid scaffold formation from the structure of human oxidosqualene cyclaseA review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic riskA Proteomic Approach to Analyze the Aspirin-mediated Lysine AcetylomeSubstitution, insertion, deletion, suppression, and altered substrate specificity in functional protocatechuate 3,4-dioxygenases.Method for comparing the structures of protein ligand-binding sites and application for predicting protein-drug interactions.Using molecular visualization to explore protein structure and function and enhance student facility with computational tools.Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaThe influence of Cox-2 and bioactive lipids on hematological cancers.Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z, 13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-(R)-hete.Different catalytically competent arrangements of arachidonic acid within the cyclooxygenase active site of prostaglandin endoperoxide H synthase-1 lead to the formation of different oxygenated products.A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirinSalicylate (salsalate) in patients with type 2 diabetes: a randomized trial.Developmental expression of functional cyclooxygenases in zebrafish.Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever.COX in a crystal ball: current status and future promise of prostaglandin research.Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase.Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.Crystal structure of protoporphyrinogen IX oxidase: a key enzyme in haem and chlorophyll biosynthesis.Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Current concepts in cyclooxygenase inhibition in breast cancer.
P2860
Q24670111-BB313B54-23DE-40B9-BF30-633A5ECB636DQ24672649-36FA4C48-7C7F-4180-8D30-C4B3765B3D1CQ24685768-40F5D996-ABCC-450D-8696-EFE6B0578D86Q26852304-ACE138C8-14E9-4002-9595-5BDD6BDD1D3DQ26861509-59C47F42-C019-4434-B185-75C1F4E732CDQ27022351-F2B8B4BC-3E2D-4D1F-918A-CECDD93C3E7DQ27628961-0DC3C1DD-3636-48B2-9240-804C195141EEQ27633719-7799C5FF-0FC0-4CC6-A47C-96F745066D05Q27663665-168C6740-A7B5-41CD-B43F-72DE946EC08DQ27671771-906BA4F1-717D-4B21-8338-3AFDBAF3B5CFQ27681344-49E99F05-BAB0-42FC-AFCE-F8B09022F199Q28174019-B06B72A2-3164-4EF4-ACA5-175957D9B558Q28177082-D82F49D9-7635-42FE-AC9C-E38D5773BFAEQ28192298-188DE3B4-672E-4AF2-86B7-F0F31AC90DDAQ28193656-0B8F3E2B-4EEB-4914-89AC-CCC887592F8EQ28194407-DF8A90AD-1880-4592-A83B-021F77607E57Q28211940-1F957CF3-5AAE-4A4D-BF99-443226F44C91Q28220600-EDA2F551-3B73-4EAF-9E18-9ABBD7D12797Q28221780-67A66CF1-A5B8-49F6-AA43-FC4FEF873DF1Q28291653-A6C31EF0-661E-456E-8DD5-D72F2B9871A1Q28301541-A4673265-B4F5-4FA9-BE0A-95EB6175C973Q28817404-EE1D8769-8D56-467A-86D7-7ACBCBE900A2Q30323021-8A15706A-2F53-4CF2-8068-A22043D54C38Q30367299-BD813545-0EAD-4CD6-9F67-EEE30B09CD81Q30398086-EA08CDA9-1293-49BE-8703-630E374D357DQ33384361-B669369A-A375-4190-8E83-56B3FE6F3EE4Q33688673-76497263-3EA5-4B32-B2F1-850FF43DFB21Q33891522-F6F71431-2635-47FE-9588-C68E475E1CF4Q33893719-92161D5E-3EA5-4BBA-A78E-7E18FD9226EDQ33952053-C074E0DA-FF66-40CB-9BD9-074AD169DB20Q34027442-5ACC21CC-6B95-4636-B850-FC4CA77140C6Q34032960-EED60C4A-C69C-41C1-A371-93BFFC1A628CQ34102619-FCEBF602-6E8D-49CE-8BF7-EA24F6B0BE83Q34272371-F34C297E-88F4-4A8B-98C4-D520DE51DFABQ34514079-701E4142-687F-44ED-AC50-6DC124215AF9Q34530950-D1E415CE-EEBA-4AB4-A986-D1655B39C35FQ34546765-12713883-2358-4AFD-99C3-3BAFC314E1EDQ34658319-2C907ECF-D8D4-42ED-A59F-974063E4E240Q34771381-CAD25ED1-25B5-46F1-A332-6A575116B46AQ34969789-EEC75490-398B-4EBE-9884-F0DD3D72AD0B
P2860
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@ast
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@en
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@nl
type
label
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@ast
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@en
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@nl
prefLabel
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@ast
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@en
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@nl
P2860
P356
P1476
The structural basis of aspiri ...... ated prostaglandin H2 synthase
@en
P2093
P2860
P304
P356
10.1038/NSB0895-637
P50
P577
1995-08-01T00:00:00Z